Results of Operations and Financial Condition. On August 4, 2026, Arvinas, Inc. announced its financial results for the quarter ended June 30, 2026 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Chief Medical Officer — Noah Berkowitz, M.D., Ph.D.: Dr. Berkowitz is leaving to pursue other opportunities.

Other Events. As previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”), for the exclusive global development, manufacturing and commercializat…

Other Events. Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. As previously disclosed, in the second quarter of 2026, the Company announced that it had completed dose escalation enrollment of the Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring Kirsten rat sarcoma ("KRAS") G12D mutations. The Company is planning to complete this Phase 1 monotherapy dose escalation clinical trial and share clinical…

Results of Operations and Financial Condition. On May 12, 2026, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…

Entry into a Material Definitive Agreement. Rigel License Agreement On May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”). Pursuant to the License Agreement, the Co…

Other Events. On May 1, 2026, the Company issued a press release announcing that the FDA has granted approval for VEPPANU™ (vepdegestrant) for the treatment of adults with ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine-based therapy. VEPPANU is the first-and-only FDA-approved PROteolysis Targeting Chimera (PROTAC) protein degrader, a type of heterobifunctional protein degra…

Results of Operations and Financial Condition. On February 24, 2026 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

President, CEO, and Chairperson — John Houston, Ph.D.: Dr. John Houston resigned from his roles as President, CEO, and Chairperson of the Board.

Results of Operations and Financial Condition. On November 5, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Costs Associated with Exit or Disposal Activities. On September 17, 2025, management of Arvinas, Inc. (the “Company’), pursuant to authority delegated by the Board of Directors of the Company (the “Board”), committed to and approved a reduction in workforce of approximately 15% across roles in functional areas of the Company primarily related to vepdegestrant commercialization. The Company expects the workforce reduction will be substantially completed during the first quarter of 2026. The Co…

Regulation FD Disclosure. On September 17, 2025, the Company issued a press release providing an update on its collaboration with Pfizer, Inc. (“Pfizer”) and announcing further actions to support value creation. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…

Other Events. On September 17, 2025, the Company issued a press release providing an update on its collaboration with Pfizer and announcing further actions to support value creation, as discussed in additional detail below. Pfizer Collaboration Update The Company and Pfizer have jointly agreed to out-license the commercialization rights to vepdegestrant to a third party. Together, the companies have begun seeking a partner with the capabilities and expertise to maximize the commercial potenti…

Results of Operations and Financial Condition. On August 6, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

President and Chief Executive Officer — John Houston, Ph.D.: Dr. John Houston plans to retire as President and CEO after a successor is appointed, but will remain as Chairperson of the Board.

Director — John Young: Mr. Young resigned from the Board of Directors and Compensation Committee.

President of Research and Development — Ian Taylor, Ph.D.: Dr. Ian Taylor resigned from his position to retire but will continue as a consultant and chair of the Scientific Advisory Board.

Costs Associated with Exit or Disposal Activities. On April 30, 2025, the Company's management, pursuant to authority delegated by the Board of Directors of the Company, committed the Company to and approved a reduction of the Company’s workforce by approximately 33% across all areas of the Company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company’s portfolio. The Company expects the workforce reduction will…

Results of Operations and Financial Condition. On May 1, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am…

Results of Operations and Financial Condition. On February 11, 2025 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: January 22, 2025 By: /s/ Andrew Saik Andrew Saik Chief Financial Officer

Entry into a Material Definitive Agreement. On January 15, 2025, Arvinas Operations, Inc. (the “Company"), a wholly owned subsidiary of the Arvinas, Inc., entered into a Lease Termination Agreement with Science Park Development Corporation (the “Landlord”). Under the terms of the Lease Termination Agreement, the lease by and between the Company and the Landlord, dated November 15, 2019, as amended by First Amendment dated as of February 27, 2020, Second Amendment dated as of January 4, 2021 a…

Other Events. On January 10, 2025, the Company announced updated guidance for the planned first- and second-line Phase 3 combination clinical trials for vepdegestrant in patients with locally advanced or metastatic ER+/HER2- breast cancer, certain upcoming milestones anticipated in 2025 and provided a corporate update. Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera ("PROTAC") ER degrader designed to harness the body’s natural protein disposal system to…

Entry into a Material Definitive Agreement. On December 31, 2024, Arvinas Operations, Inc. (the “Company”), a wholly owned subsidiary of Arvinas, Inc., entered into the Eighth Amendment to Lease (the “Eighth Building 5 Lease Amendment”) with Science Park Development Corporation (the “Landlord”). The Eighth Building 5 Lease Amendment further amends that certain Lease, executed on or about January 2, 2018, by and between the Company and the Landlord (as amended on May 23, 2018, September 4, 201…

Entry into a Material Definitive Agreement. On December 13, 2024, Arvinas Operations, Inc. (the “Company”), a wholly owned subsidiary of Arvinas, Inc., entered into a Seventh Amendment to Lease (the “Seventh Building 5 Lease Amendment”) with Science Park Development Corporation (the “Landlord”). The Seventh Building 5 Lease Amendment further amends that certain Lease, executed on or about January 2, 2018, by and between the Company and the Landlord (as amended on May 23, 2018, September 4, 20…